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Abstract
This study investigates the effects of a site-directed TG2-selective inhibitor on the lung myofibroblast phenotype and ECM 
deposition to elucidate TG2 as a novel therapeutic target in idiopathic pulmonary fibrosis (IPF)—an incurable progressive 
fibrotic disease. IPF fibroblasts showed increased expression of TG2, α smooth muscle actin (αSMA) and fibronectin (FN) 
with increased extracellular TG2 and transforming growth factor β1 (TGFβ1) compared to normal human lung fibroblasts 
(NHLFs) which do not express αSMA and express lower levels of FN. The myofibroblast phenotype shown by IPF fibroblasts 
could be reversed by selective TG2 inhibition with a reduction in matrix FN and TGFβ1 deposition. TG2 transduction or 
TGFβ1 treatment of NHLFs led to a comparable phenotype to that of IPF fibroblasts which was reversible following selective 
TG2 inhibition. Addition of exogenous TG2 to NHLFs also induced the myofibroblast phenotype by a mechanism involving 
TGFβ1 activation which could be ameliorated by selective TG2 inhibition. SMAD3-deleted IPF fibroblasts via CRISPR-
cas9 genome editing, showed reduced TG2 protein levels following TGFβ1 stimulation. This study demonstrates a key role 
for TG2 in the induction of the myofibroblast phenotype and shows the potential for TG2-selective inhibitors as therapeutic 
agents for the treatment of fibrotic lung diseases like IPF.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is an incurable and life-
threatening disease with a median survival rate of 2–3 years 
in the UK (Strongman et al. 2018). The most common cause 
of death is respiratory failure, accounting for over 80% of 
deaths (Raghu et al. 2006). Histological analysis of IPF sam-
ples show thick collagen and ‘fibroblast foci’ in areas of 
fibrosis (Kekevian et al. 2014). Increased proliferation of 
fibroblasts and excessive deposition of extracellular matrix 
(ECM) proteins above the rate of ECM degradation char-
acterises IPF (Dragsbaek et al. 2015; Ramos et al. 2001). It 
has been demonstrated by Mora et al. that there has been a 
high attrition rate for drugs that enter clinical trials for the 
treatment of IPF, and, therefore, this highlights the demand 
for promising new targets to be identified (Mora et al. 2017).
Transglutaminase 2 (TG2), is a calcium-activated mul-
tifunctional enzyme, well known for the formation of ε-(γ-
glutamyl)lysine isopeptide bonds that lead to protein cross-
linking, that provide resistance to proteolytic cleavage and 
ultimately, stabilisation and increased stiffness of the ECM 
(Bergamini et al. 2011; Wang and Griffin 2012). TG2 is 
reported to have various pathological roles, including cancer 
metastases (Ayinde et al. 2017; Kotsakis et al. 2011; Wang 
and Griffin 2013), coeliac disease (Nadalutti et al. 2013) and 
tissue fibrosis (Badarau et al. 2015; Wang et al. 2018). TG2 
knockout (KO) mice show reduced fibrosis in response to 
bleomycin-induced pulmonary fibrosis, including a marked 
reduction in collagen deposition (Oh et al. 2011). How-
ever, the actual mechanism(s) of TG2′s role in IPF remains 
unknown. Importantly, TG2-selective inhibitors have not yet 
been tested in IPF.
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Use of irreversible small molecule TG2 inhibitors in a rat 
diabetic nephropathy model showed that TG2 inhibition led 
to reduced glomerulosclerosis and tubulointerstitial fibrosis 
by up to 77% and 92%, respectively (Johnson et al. 2007). 
Recently, the TG2-selective and irreversible inhibitor 1–155 
used in this study and developed at Aston University resulted 
in upto a 40% reduction in collagen deposition in a mouse 
Angiotensin II model of nephrosclerosis and a 60% reduc-
tion in infarct size in an acute myocardial infarction mouse 
model (Badarau et al. 2015; Wang et al. 2018). These previ-
ous studies demonstrate the potential of site-directed TG2-
selective inhibitors for the treatment of tissue fibrosis.
Apart from its importance in generating a protease-
resistant crosslinked fibrotic matrix, TG2 can release the 
active transforming growth factor β1 (TGFβ1) from ECM 
via crosslinking the large latent TGFβ1-binding protein 
(LTBP)-TGFβ1 complex in the ECM (Verderio et al. 1999). 
TGFβ1 is a crucial pro-fibrotic cytokine that promotes fibro-
sis via fibroblast-to-myofibroblast transition (Wang et al. 
2018), epithelial–mesenchymal transition (EMT) (Nya-
bam et al. 2016) and endothelial–mesenchymal transition 
(EndMT) (Wang et al. 2017), promoting myofibroblast acti-
vation, inducing ECM protein expression and deposition and 
inhibiting matrix degradation pathways leading to matrix 
accumulation.
Here we demonstrate how TG2 is involved in inducing the 
myofibroblast phenotype in IPF cells. We also demonstrate 
the potential of using site-directed TG2-selective inhibitors 
as therapeutic agents for IPF. We show that these inhibitors 
can reduce matrix deposition and reverse the myofibroblast 
phenotype in IPF via preventing the activation of TGFβ1, 
reducing myofibroblast biomarkers and inhibiting excessive 
matrix protein deposition.
Results
Increased expression of TG2 and myofibroblast 
markers in IPF fibroblasts
Previous research has identified that IPF is associated with 
an increase in the myofibroblast presence and excessive 
ECM deposition (Olsen et al. 2011). TG2 was significantly 
upregulated in IPF fibroblasts, in comparison to NHLFs 
(Fig. 1a and b) with IPF fibroblasts showing a significant 
increase in both FN and α smooth muscle actin (αSMA), 
compared to NHLFs. Increased levels of TG2, fibronectin 
(FN) and TGFβ1 were also detected in the ECM fractions 
deposited by IPF fibroblasts when compared to NHLFs 
(Fig. 1c and d).
Overexpression of active TG2 leads 
to a myofibroblast phenotype in NHLFs
Wild-type (wt) TG2 overexpression in NHLFs via lentivi-
ral transduction gave rise to increased TG2 protein levels 
Fig. 1  Characterisation of 
NHLFs and IPF fibroblasts. a 
Representative Western blots 
of TG2, FN and αSMA in the 
cell lysates of NHLFs and IPF 
fibroblasts. GAPDH was used to 
normalise loading. c Repre-
sentative blots of TG2, FN and 
TGFβ1 in ECM fractions of 
NHLFs and IPF fibroblasts. b 
and d are graphs showing mean 
densitometry values ± S.D. 
with the NHLFs taken as 1.0. *, 
p < 0.05; **, p < 0.01; and ***, 
p < 0.001
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in comparison to non-transduced or control virus-trans-
duced NHLFs (Fig. 2a and b). A transamidating-inactive 
mutant TG2 (C277S-TG2) (Balklava et al. 2002) was also 
overexpressed in NHLFs to understand the importance of 
the transamidating activity of TG2 (Fig. 2c–f). Western 
blotting showed significant increases in TG2 expression 
confirming successful transduction of both wild type and 
C277S mutant TG2 compared to control vector trans-
duced and wild type NHLFs. As expected, both FN and 
αSMA expression were increased in wild-type TG2-trans-
duced NHLFs; however, no increases in FN and αSMA 
were detected in the inactive C277S-TG2 trarnsduced 
NHLFs (Fig. 2c–f). Increases in Smad3 phosphorylation 
(p-Smad3) was only detected in the wild type active TG2 
transduced NHLFs when compared to the vector control 
and C277S mutant transduced cells (Fig. 2g and h) con-
firming the importance of active TG2 in myofibroblast 
formation.
TGFβ1 involvement in the TG2‑regulated 
myofibroblast transition in NHLFs
Our previous work suggested that TGFβ1, a pro-fibrotic 
cytokine known to increase during fibrosis can upregu-
late TG2 expression (Nyabam et  al. 2016; Wang et  al. 
2018). Fluorescence staining of TG2 in NHLFs confirmed 
increased TG2 expression following stimulation of NHLFs 
with TGFβ1 (Fig.  3a and b).Cell surface biotinylation 
revealed higher levels of cell surface TG2, confirmed using 
Na + /K + ATPase as a cell surface marker, in TGFβ1-treated 
NHLFs (Fig. 3c and d), while a significant increase in ECM 
TG2 was also found in these cells (Fig. 3e and f), accompa-
nied with increased FN deposition (Fig. 3e and f).
Exogenous active TG2 leads to a myofibroblast 
phenotype in NHLFs via TGFβ1
Given that TG2 and TGFβ1 can form a positive feedback 
cycle in driving myofibroblast transition, including cystic and 
Fig. 2  Overexpression of catalytically active TG2 in NHLFs induces 
Smad3 signalling and a myofibroblast phenotype. a Representa-
tive Western blot of TG2 in NHLFs cell lysates following lentiviral 
transduction. VC, vector control. b, c Representative Western blots of 
TG2, FN and αSMA in NHLFs transduced with empty vector (VC), 
wt-TG2 and C277S-mutant TG2 (C277S-TG2). d–g Representa-
tive Western blots of p-Smad3 in VC, wt-TG2 and C277S-TG2 len-
tivirus transduced NHLFs. Graphs based on densitometry analysis 
of Western blots are shown in b–f and h expressed as a mean fold 
change ± SEM compared with VC or NHLFs control taken as 1.0. 
GAPDH was used to ensure equal loading. *, p < 0.05; **, p < 0.01; 
***, p < 0.001; and NS, not significant
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cardiac fibrosis (Nyabam et al. 2016; Wang et al. 2018), we 
next studied whether addition of exogenous TG2 to NHLFs 
can lead to their transition into myofibroblasts. Figure 4a and 
b shows that the addition of exogenous rh-TG2 resulted in an 
increase in TG2 protein levels in NHLFs cell lysates. Impor-
tantly, exogenous TG2 treatment also increased FN and αSMA 
expression, compared to untreated NHLFs (Fig. 4a and b), 
which was accompanied by higher levels of ECM TG2, FN 
and TGFβ1 (Fig. 4c and d). Compared to the control NHLFs, 
introduction of Rh-TG2 to NHLFs triggered the activation 
of SMAD3 (p-SMAD3) within 2 h to around 2.5 times the 
control which subsequently declined to around 1.5 times the 
control NHLFs value after 6 h (Fig. 4e and f). This suggests 
that exogenous TG2 is acting via induction of TGFβ signal-
ling which is supported by the finding of a 70% increase of 
active TGFβ in the culture medium of TG2 treated IPF cells 
measured using the Mink lung epithelial cells (MLECs) 
reporter system (Fig. 4g) and the presence of increased active 
TGFβ in the matrix of TG2 treated NHLFs (Fig. 4c).
In addition, treatment of NHLFs cells with inhibitors of 
ERK signalling, ALK5 receptor or a TGFβ neutralising anti-
body (TGFβ-NA) all resulted in the inhibition of the increased 
expression of TG2, FN and αSMA induced by exogenous TG2 
(Fig. 4h–j), confirming that exogenous TG2 functions through 
the TGFβ1 pathway(s) in inducing TG2, FN and increased 
TGFβ in NHLFs.
Fig. 3  TGFβ1 stimulation of NHLFs regulates TG2 protein levels and 
ECM deposition. a Representative images of TG2 staining (green) 
in NHLFs treated with different concentrations of TGFβ1 with Hoe-
chst (blue) staining. b Dose–response curve of TG2 levels against log 
TGFβ1 concentration. Mean percentage increase ± SEM in cell count 
(blue) also shown. The images were quantified as described in “Mate-
rials and methods”. c–f Representative Western blots of TG2 in cell 
surface and cell lysates c and matrix TG2 and FN f following treat-
ment of NHLFs with TGFβ1 (1 ng/ml). Na + /K + ATPase was used 
as a cell surface loading control. Graphs based on densitometry anal-
ysis of Western blots with controls normalised to 1.0 are shown in d 
and f. GAPDH was used to ensure equal loading for cell lysates. Data 
are shown as a mean fold change ± SEM of control cells. **, p < 0.01; 
and ***, p < 0.001
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Selective inhibition of TG2 reverses 
the TGFβ1‑induced myofibroblast phenotype 
in NHLFs
Selective inhibitors of TG2 can reduce heart and kidney 
fibrosis (Badarau et al. 2015; Wang et al. 2018); however, 
this has not been tested in IPF. Figure 5a and b show that 
TG2-selective inhibitor 1–155 and a non-cell permeable 
TG2 inhibitor R281 were able to significantly reduce the 
in situ TG2 activity in NHLFs induced by TGFβ1 treatment. 
Similarly, 1–155 treatment decreased the TGFβ1-induced 
expression of TG2 and FN (Fig. 5c–e) and reduced matrix 
deposition (Fig. 5f–h) of TG2 and FN. Importantly, 1–155 
and R281 treatment was able to block the TGFβ1-induced 
myofibroblast marker αSMA in NHLFs (Fig. 5i and j).
TGFβ1‑mediated TG2 expression involves Smad3
TG2 expression has been reported to be regulated via the 
non-canonical TGFβ1 pathway through the activation of 
ERK1/2 in NHLFs (Olsen et al. 2011), but the role of the 
TGFβ1 canonical pathway via SMADs has not been stud-
ied. Our data so far suggest that the involvement of TGFβ1 
canonical pathway via Smad3 is involved in TG2-mediated 
myofibroblast transition in NHLFs and IPF fibroblasts. 
To confirm this, we used CRISPR-Cas9 genome editing 
to knockout Smad3 protein expression (SMAD3-KO) and 
TG2 expression (TG2–KO) in IPF fibroblasts. TG2 expres-
sion was then measured via immunofluorescence staining in 
SMAD3-KO and TG2-KO cells both in the absence (Fig. 6a 
and b) and presence of TGFβ1 stimulation (Fig. 6c and d). 
TG2-KO IPF fibroblasts which had around 65% of cells 
with TG2 gene editing, failed to respond to TGFβ1 stimu-
lation. Smad3-KO IPF fibroblasts which had around 60% 
of cells showing the absence of Smad3 expression showed 
no significant change in TG2 expression compared to WT 
IPF fibroblasts in unstimulated conditions (Fig. 6a and b). 
However, SMAD3-KO IPF fibroblasts did show a significant 
decrease (approx. 25%) in TG2 expression following TGFβ1 
treatment, compared to wild-type IPF fibroblasts (Fig. 6c 
Fig. 4  The effect of Rh-TG2 stimulation on NHLFs lysate and matrix 
protein levels. a Representative Western blots of TG2, FN and αSMA 
and c matrix TG2, FN and monomeric TGFβ1 in NHLFs treated with 
exogenous Rh-TG2 (1  µg/ml) and untreated NHLFs. e Representa-
tive Western blots of p-SMAD3 and t-SMAD3 in control NHLFs and 
NHLFs treated with 1 µg /ml Rh-TG2 for 2 or 6 h. g Graph showing 
the presence of active TGFβ in IPF fibroblasts treated with Rh-TG2 
(1  µg/ml) via the Mink TGFβ reporter system as described in the 
“Materials and methods”. h Representative Western blots of TG2 
and FN in NHLFs treated with an ERK inhibitor (10 µM), a TGFβ 
neutralising antibody (20 µg/ml) or an Alk5 inhibitor (10 µM) in the 
presence of Rh-TG2 (1 µg/ml). Graphs based on densitometry analy-
sis of Western blots with controls normalised to 1.0 are shown in b–i 
and j expressed as a mean fold change ± SEM. GAPDH was used to 
ensure equal loading. *, p < 0.05; **, p < 0.01; and ***, p < 0.001
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and d), confirming the importance of Smad3 in TGFβ1 regu-
lated TG2 expression.
Selective TG2 inhibition can reverse 
the myofibroblast phenotype in IPF fibroblasts
We next treated IPF fibroblasts with TG2 inhibitors to 
explore the potential of selective TG2 inhibition as a thera-
peutic avenue for IPF. IPF fibroblasts were treated with the 
extracellular acting TG2 inhibitor R281 (500 µM) and the 
TG2-selective inhibitor 1–155 (2.5 µM) for 72 h. Figure 7a 
and b show that both TG2-selective cell-permeable inhibi-
tor 1–155 and cell-impermeable inhibitor R281 reduced 
TG2 expression in IPF fibroblast lysates, accompanied 
with significant decreased expression of FN and αSMA 
(Fig. 7a, c and d) and reduced TG2, FN and monomeric 
TGFβ1deposition in the ECM (Fig. 7e–h).
Figure 7i and j demonstrate that treatment of IPF fibro-
blasts with cell impermeable TG2 inhibitor R281 led to a 
reduction in p-SMAD3 levels compared to the control IPF 
fibroblasts, with p-ERK1/2 levels also decreasing in the 
presence of R281 (Fig. 7k and l). To gain a greater under-
standing of the regulation of TG2 expression, IPF fibroblasts 
were treated with an inhibitor of ERK and an ALK5 receptor 
inhibitor. Both ALK5 and ERK inhibition led to a reduction 
in TG2 expression compared to the control IPF fibroblasts 
(Fig. 7m and n).
Discussion
The involvement of TG2 in lung fibrosis was first proposed 
by (Griffin et  al. 1979). Later studies have now shown 
that increased expression of TG2 is found in the lungs of 
IPF patients and that TG2-KO mice develop significantly 
reduced bleomycin-induced fibrosis compared to wild-type 
mice (Olsen et al. 2014). This same group investigated two 
small electrophilic compounds CDDO and 15d-PGJ2 that 
Fig. 5  TG2-selective inhibitors prevent the TGFβ1-induced increases 
in TG2 activity, the myofibroblast phenotype and ECM protein depo-
sition. a TG2 in situ activity measured via FITC-cadaverine incorpo-
ration following treatment of NHLFs with TGFβ1 (1 ng/ml) and TG2 
inhibitors (1–155 and 281). TG2 activity (green) and DAPI (blue). 
b Relative fluorescent signals of treated NHLFs against the control. 
Control fluorescent signals were normalized to 100%. Fluorescent 
signals were measured via ImageJ software. c Representative West-
ern blots of TG2 and FN in control and NHLFs treated with TGFβ1 
and TG2 inhibitor 1–155. f Representative Western blots of TG2 and 
FN from ECM fractions of NHLFs treated with TGFβ1 and TG2 
inhibitor 1–155. i Representative Western blots of αSMA in control 
NHLFs, TGFβ1-treated NHLFs and NHLFs treated with TG2 inhibi-
tor 1–155 or R281 with TGFβ1. Graphs based on densitometry analy-
sis of Western blots with controls normalised to 1.0 are shown in b–h 
and j. GAPDH was used to ensure equal loading data in the graphs 
are expressed as a mean fold change ± SEM compared to the control 
NHLFs. *, p < 0.05; **, p < 0.01; and ***, p < 0.001
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were reported to block myofibroblast formation and matrix 
deposition in normal human fibroblasts (Olsen et al. 2011). 
They demonstrated that in normal and IPF-derived fibro-
blasts that TG2 expression was reduced by these two small 
molecules although in IPF derived fibroblasts this reduc-
tion in TG2 expression was less effective. They concluded 
that the ability of these small molecules to reduce TG2 
expression and inhibit fibrosis was via inhibition of ERK 
signalling.
More recent studies have demonstrated that the pan trans-
glutaminase inhibitor cystamine reduces collagen deposition 
in the mouse bleomycin model of lung fibrosis (Philp et al. 
2018). However, unlike selective TG2 inhibitors such as 
1–155 used in this study, cystamine inhibits other transglu-
taminases, as well as cysteine proteases, such as Caspase 3.
In this paper, we confirm previous data showing that 
TG2 protein levels are significantly increased in IPF fibro-
blasts compared to NHLFs (Olsen et al. 2014). In addition, 
we demonstrate that treatment of primary IPF fibroblasts 
with a TG2-selective inhibitor 1–155 and a cell imperme-
able TG2 inhibitor R281 reverses the myofibroblast pheno-
type with reduced expression of FN, TG2 and αSMA and 
reduced deposition into the ECM of TG2, FN and TGFβ1. 
These data are in keeping with our previous data showing 
that TGFβ1 induction of cardiofibroblasts into myofibro-
blasts and the parallel increase in matrix deposition could 
be inhibited using selective TG2 inhibitor 1–155, which 
when translated into mouse models of cardiac fibrosis 
and nephrosclerosis indicated that treatment with 1–155 
caused a significant reduction of collagen deposition in 
these different animal models. Hence it is not unreasonable 
to assume that TG2 selective inhibitors like 1–155 are able 
to reduce fibrosis in animal models of lung fibrosis such 
as the bleomycin model commonly used for preclinical 
studies.
Our findings confirm previous studies in that over-expres-
sion of TG2 in NHLFs leads to increased matrix protein 
levels (Olsen et al. 2014). In addition, our study also shows 
that over-expression of TG2 in NHLFs leads to upregulation 
of αSMA protein levels compared to control cells; however, 
previous research by Olsen et al. found no differences in 
αSMA protein (Olsen et al. 2014). NHLFs express very 
low levels of αSMA, but research by Olsen et al. showed 
αSMA protein levels to be relatively high in NHLFs trans-
duced with a control virus (Olsen et al. 2014). However, we 
did not encounter any phenotype changes in empty vector 
transduced NHLFs. Our study revealed a marked increase 
in αSMA protein levels following over-expression of TG2 
Fig. 6  CRISPR-Cas9 genome editing was performed on IPF fibro-
blasts targeting the Smad3 and TGM2 gene. IPF fibroblasts under-
went CRISPR-Cas9 genome editing as described in the “Materials 
and methods” targeting the SMAD3 and TGM2 genes. Representa-
tive images of immunocytochemistry staining of TG2 in the TG2 KO, 
SMAD3 KO and WT IPF fibroblasts in the absence a and presence c 
of TGFβ1 stimulation. TG2 (green), Hoechst (blue). b and d Graphs 
present the percentage of the signals measured via immunocyto-
chemistryas described in the “Materials and methods”. Quantitative 
data was generated using the ‘Mean_TargetAvgIntenCh2′ algorithm 
and the ‘AP30704v1_SIAJCollagenandCellCountCellHealth (V01)’ 
protocol. Data are expressed as a percentage of control ± SEM. **, 
p < 0.01; and ***, p < 0.001
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in NHLFs compared to the low levels of αSMA protein in 
NHLFs transduced with control virus.
TGFβ1 has previously been reported to upregulate TG2 
expression by activating the TGFβ1 response element 
located within the TGM2 gene promoter (Nunes et al. 1997) 
which supports our observations within this study. Further-
more, knockout of SMAD3 in IPF cells by CRISPR-Cas9 
genome editing suggests that TGFβ1 also utilises SMAD3 
signalling for the upregulation of TG2. However, our data 
also show that SMAD3 is not the sole regulator of TGFβ1-
induced upregulation of TG2. Previous research identified 
a phosphorylation signalling cascade involving ERK activa-
tion also regulates TG2 expression and targeting ERK with 
inhibitors could reduce TG2 expression in fibrotic lung 
fibroblasts (Olsen et al. 2011). This suggests that TGFβ1-
induced upregulation of TG2 is likely to be regulated by 
both canonical (SMAD3) and non-canonical (ERK) TGFβ1-
induced signalling which may explain why 60% knockout 
of SMAD 3in IPF fibroblasts only gave rise to around 25% 
decrease in TG2 expression when compared to control cells.
We show that addition of exogenous TG2 to NHLFs 
leads to increased expression of TG2, FN and αSMA, with 
increased matrix deposition of TG2, FN and activated 
TGFβ1. We also show that addition of TG2 to IPF cells 
which already show the myofibroblast phenotype leads to 
a significant increase in active TGFβ1 levels in the cul-
ture medium. Since TG2 inhibition blocked this response 
in NHLFs, this suggests that the increased TGFβ1 levels 
are resulting from TG2 activation of latent matrix-bound 
TGFβ1,through a mechanism demonstrated by (Nunes et al. 
1997).This in turn leads to induction of the myofibroblast 
phenotype since both the cell impermeable inhibitor 281 
and the cell permeable inhibitor 1–155 which acts both at 
the intra-and extracellular level blocked expression of both 
TG2 and the myofibroblast marker αSMA. It has also been 
reported that TG2 crosslinking of the ECM can lock active 
TGFβ1 into the matrix which may be a mechanism for pro-
longing the half-life and creating an active reservoir of this 
transient growth factor (Nyabam et al. 2016; Wang et al. 
2017). This phenomenon has also been observed with VEGF 
(Wang et al. 2013). Further support for such a mechanism 
comes from the finding that when TGFβ is incorporated into 
TG crosslinked collagen it remains active and capable of 
cell signalling (Niger et al. 2013). Addition of exogenous 
Fig. 7  Treatment of IPF fibroblasts with TG2-specific inhibitors 
and the relationship with Smad3 and ERK1/2 signalling pathways. 
a Representative Western blot of TG2, FN and αSMA in control 
IPF fibroblasts and IPF fibroblasts treated with either TG2 inhibitor 
1–155 (2.5  µM) or R281 (500  µM). e Representative Western blots 
of TG2, FN and TGFβ1 from ECM fractions of IPF cells treated as 
shown. i Representative Western blots of p-SMAD3 and t-SMAD3 
and k p-ERK1/2 and t-ERK1/2 in the control IPF fibroblasts and 
R281 treated IPF fibroblasts. m Representative Western blots of 
TG2 in control IPF fibroblasts and IPF fibroblasts treated with an 
ALK5 or an ERK inhibitor. Graphs based on densitometry analysis 
of Western blots with controls normalised to 1.0 are shown in b–l 
and n. GAPDH was used to ensure equal loading data in the graphs 
are expressed as a mean fold change ± SEM compared to the control 
NHLFs *, p < 0.05; **, p < 0.01; and***, p < 0.001
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TG2 also led to an increase in activated TGFβ1 presence in 
the ECM, which supports this theory. Importantly in rela-
tion to in vivo studies (Johnson et al. 2007), TG2 has been 
shown to be found in high levels in the extracellular matrix 
where it will activate matrix bound latent TGFβ1 leading to 
a positive feedback-loop between TG2 and TGFβ1 which 
we demonstrate in primary NHLFs. Targeting TG2 using 
TG2-selective inhibitors can disrupt this pro-fibrotic feed-
back loop preventing progressive fibrosis from occurring 
as we demonstrated in both cardiac (Wang et al. 2018) and 
kidney fibrosis mice models (Badarau et al. 2015; Johnson 
et al. 2007).
Previous researchers have suggested that TG2 activity is 
critical for the extracellular crosslinking of ECM proteins 
that leads to proteolytic-resistant fibrotic lesions (Collighan 
and Griffin 2009). We demonstrate that treatment of TGFβ1-
stimulated NHLFs with a TG2-selective inhibitor leads to a 
reduction in TG2 activity, myofibroblast transition and ECM 
deposition of TG2, FN and activated TGFβ1. Furthermore, 
TG2 inhibition prevented the increase in FN expression and 
importantly prevented the increase in expression of the key 
myofibroblast marker αSMA, whose expression could also 
be inhibited by the cell impermeable TG2 inhibitor 281 con-
firming TG2′s action on TGFβ1 is occurring outside the cell. 
Moreover, TG2 inhibition prevented the increase in FN and 
αSMA expression that was induced by over-expression of 
TG2 in NHLFs both in the presence and absence of TGFβ1. 
These data further support our hypothesis that inhibition 
of TG2 using either a cell permeable or cell impermeable 
inhibitor prevents the positive-feedback loop between TG2 
and TGFβ1, leading to reduced myofibroblast presence and 
excessive deposition of ECM proteins.
Previous research showed that TGFβ stimulation of 
healthy lung fibroblasts leads to an increase in ECM and 
cell surface levels of TG2 but no change in cytosol TG2 
was observed following stimulation (Olsen et al. 2011). In 
contrast, we found that TG2 protein levels were significantly 
increased in both whole cell lysates and in the ECM follow-
ing treatment with TGFβ1 which may be due to the different 
concentrations of TGFβ1 used in the two studies.
In conclusion, using active site-directed inhibitors that 
are selective for TG2, we demonstrate that this multifunc-
tional enzyme is critical for maintenance of the myofibro-
blast phenotype in primary IPF fibroblasts. We show that 
extracellular TG2 is an important regulator of TGFβ1 activ-
ity and TGFβ1-induced lung myofibroblast formation which 
leads to a vicious cycle involving increased TGFβ activation, 
increased expression and extracellular activity of TG2 and 
increased ECM deposition (Fig. 8). Importantly, this study 
confirms the importance of TG2 as promising therapeutic 
target for the treatment of IPF.
Materials and methods
Chemicals
General chemicals used within this study were purchased 
from Sigma-Aldrich (UK) unless stated otherwise.
Cells
Primary NHLFs and Human IPF Fibroblasts cells were sup-
plied by GSK (UK). The cells were used up to a maximum 
of passage 8. MLECs were gifted by Professor Daniel Rifkin 
(New York University, USA).
Cell culture
NHLFs and IPF fibroblastss were cultured in complete 
DMEM containing Ultraglutamine (glutamine 4.5 g/l), 1% 
(v/v) non-essential amino acids (NEAA) and 10% (v/v) 
Fig. 8  Schematic showing how 
TG2 inhibitors block fibrosis 
during IPF. The vicious cycle 
between TG2 and TGFβ1 leads 
to the transformation of lung 
fibroblasts into myofibroblasts 
which subsequently results in 
the increase of fibrotic tissue 
and further active TGFβ1, 
leading to sustained expression 
of TG2. Inhibiting this vicious 
cycle using selective TG2 inhib-
itors attenuates the progression 
of fibrosis during IPF
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foetal calf serum (FCS) supplementation. MLECs were 
cultured in complete DMEM containing 2 mM glutamine, 
10% (v/v) FCS and 250 μg/ml G418 sulphate. The medium 
was changed every 48 to 72  h. NHLFs and IPF fibro-
blasts were maintained at 37 °C in a 10%  CO2-humidified 
incubator, whilst MLECs were cultured at 37 °C in a 5% 
 CO2-humidified incubator.
Cell treatments
TG2-selective inhibitor 1–155 (Badarau et al. 2015) and 
extracellular-acting TG2 inhibitor R281 (Badarau et al. 
2013) were synthesised in Aston University laboratories. 
Recombinant human TG2 (Rh-TG2) was from Zedira (Ger-
many). Transforming growth factor β1 (TGFβ1) and ERK 
inhibitor (PD98059) were purchased from R and D Systems 
(UK).
Lentiviral transduction of NHLFs
NHLFs were transduced with lentiviral particles containing 
TG2 and a control empty lentivirus. Lentiviral transduction 
was performed as previously described (Wang et al. 2013). 
Cells were cultured to 80% confluency in a 60 mm Petri dish, 
followed by two rounds of lentiviral transduction. The trans-
duction efficiency was confirmed using Western blotting.
CRISPR‑Cas9 gene editing
The gRNAs were designed using a free online tool (Desk-
gen). The two gRNA sequences used for TG2 KO were 
’GTC TTG CTG GTC CAC CAC GG’ and ’TGA GGC GAT 
ACA GGC CGA TG’ which both target exon 3 in the TGM2 
gene. For SMAD3 gene deletion the cells used in this study 
and the gRNA sequence used to achieve gene editing of 
Smad3 was ‘GAG CTG ACA CGG AGA CAC AT’ as pub-
lished by Martufi et al. with only a single RNA electropo-
ration performed using the method described in the same 
paper (Martufi et al. 2019). Briefly, the gRNA was diluted 
in nuclease-free duplex buffer at 25 µM before boiling at 
95 °C for 5 min and then cooling for a further 10 min at RT. 
The RNA (72.5 pmol) was then complexed with the Cas9 
enzyme (60 pmol) and incubated at RT for 10 min before 
adding 60 pmol of electroporator enhancer and incubating 
for a further 5 min at RT. IPF fibroblasts (2.5 × 105 cells) 
were then washed with PBS, pH 7.4, before being pelleted 
by centrifugation at 90 × g for 10 min. The cells were re-sus-
pended in 15.5 µl P3 solution (Lonza, UK) and then 4.5 µl 
of the gRNA complex was added. The electroporation was 
performed in 16-well Nucleocuvette strips. The IPF fibro-
blasts were then plated into a 24-well plate and incubated 
in a 37 °C, 10%  CO2-humidified incubator for 24 h. The 
next-generation sequencing and analysis was performed by 
Matteo Martufi (GlaxoSmithKline).
MLEC TGFβ reporter assay
Active TGFβ levels were measured using the MLEC TGFβ 
reporter assay (Abe et al. 1994). Fibroblasts were seeded at 
a density of 5 × 104 cells/well in a 96-well plate in DMEM 
containing 0.4% FCS. Rh-TG2 was immediately added to the 
appropriate wells and then the plate was incubated at 37 °C 
in a 10%  CO2-humidified incubator for 16–24 h. Following 
the incubation, MLECs were seeded at a density of 2.5 × 104 
cells/well in a collagen-coated 96-well plate using DMEM 
containing 0.4% FCS and G418 sulphate (250 µg/ml). The 
MLECs were incubated at 37 °C in a 5%  CO2-humidified 
incubator for 3 h before replacing the medium with medium 
taken from the fibroblasts. The MLECs were cultured 
overnight with medium from fibroblasts at 37 °C in a 5% 
 CO2-humidified incubator before replacing the medium with 
serum-free medium. Bright-Glo reagent (Promega) was then 
added to the serum-free medium and the plate was incubated 
for 2 min before transferring the total volume to a white-
walled 96-well plate. The plate was read on a SpectraMax-L 
luminescent plate reader.
In situ TG2 activity using FITC‑cadaverine 
incorporation
In situ TG2 activity assay was performed as described pre-
viously (Jones et al. 2013). Fibroblasts were seeded at a 
density of 8 × 104 cells/well in an 8-well chamber slide and 
incubated overnight in a 37 °C, 10%  CO2-humidified incuba-
tor. Fresh medium and treatments were then added before 
replacing these after 24 h. Following 48-h incubation with 
treatments, fresh medium containing 0.5 mM FITC-cadav-
erine was added and incubated for further 16 h in a 37 °C, 
5 or 10%  CO2-humidified incubator. Following the incuba-
tion, medium was discarded and the cells were washed three 
times with PBS, pH 7.4. The cells were fixed with 3.7% 
(v/v) paraformaldehyde in PBS, pH 7.4, for 15 min at RT 
before washing three times with PBS, pH 7.4. The slide was 
mounted with Vectorshield mounting medium and detected 
using confocal microscopy. Quantification of fluorescence 
was performed using ImageJ software.
Western blotting
Cell lysates were collected in cell lysis buffer [50 mM 
Tris–HCl, pH 7.4, containing 1% (v/v) nonidet, 0.5% 
(w/v) Sodium deoxycholate, 0.1% SDS, 1 mM NaF, 1 mM 
 Na3VO4, 2 mM EDTA, 0.1 mM PMSF (in methanol) and 
1% protease inhibitor cocktail] (Wang et al. 2010). Protein 
concentration was calculated using a DC Protein Assay kit 
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(Bio-Rad, UK). Proteins were separated using reducing 
SDS-PAGE and transferred to a nitrocellulose membrane. 
The membranes were immuno-probed with protein-specific 
antibodies (Table 1). The Western blotting protocol was per-
formed as described previously (Wang et al. 2011, 2012). 
The membrane was stripped and re-probed for GAPDH as an 
equal loading control that was used to normalize the signal 
for the target protein in cell lysates.
For matrix protein analysis where no suitable loading 
standard was available, equal cell numbers were always 
used at the start of the experiment. To obtain the cell matrix 
proteins, gentle removal of cells was undertaken using 5 mM 
EDTA in PBS, pH74, and the remaining matrix proteins 
dissolved via scraping into equal volumes of 2 × Laemli 
buffer (30 µl). The total matrix from each sample was then 
loaded onto SDS PAGE gels. The western blotting protocol 
was undertaken as described previously (Wang et al. 2011, 
2012). Parallel experiments on the analysis of viable cell 
numbers with or without treatment with TGF β1 for 72 h 
indicated that the viable cell numbers were comparable in 
the TGFβ1 treated and untreated cells (data not shown).
Following primary and secondary antibody incubation, 
images were captured by a chemiluminescent image ana-
lyser Syngene G-box F3 (Cambridge, UK). Densitometry 
was performed with ImageJ software. The intensity of the 
bands was normalized against the GAPDH band. The ratios 
are shown against controls (normalized as 1.0). Data are 
expressed as mean ratios ± SEM taken from at least three 
separate experiments unless stated.
Cell surface TG2 protein detection via biotinylation
Cells were seeded at a density of 5 × 105 cells/60 mm Petri 
dish and incubated for 2 h before treatments were added. 
The cells were then incubated for 24 h at 37 °C in a − 10% 
 CO2-humidified incubator. The presence of TG2 at the cell 
surface was detected via biotinylation (Wang et al. 2012) 
with EZ-link Sulfo-NHS-Biotin (Thermo, UK) according 
to the manufacturer’s protocol and analysed via Western 
blotting.
Isolation of ECM fractions
ECM fractions of the cell cultures were collected as 
described previously (Wang et al. 2018). Cells were seeded 
in 35 mm Petri dishes at a density of 2 × 105 cells/dish. 
Treatments were performed for 72 h before ECM fractions 
were collected. Cell detachment was performed with 5 mM 
EDTA in PBS, pH 7.4. The dish was then washed twice 
with PBS, pH 7.4. The ECM was collected by dissolution 
in 2 × Laemmli buffer and then underwent protein analysis 
using Western blotting.
Statistical analysis
Results shown are mean values ± SEM with data taken from 
at least three separate experiments unless otherwise stated. 
The statistical significance between data groups was cal-
culated using either a two-tailed t test or one-way ANOVA 
using GraphPad Prism. Following analysis using ANOVA, 
a Tukey post hoc test was performed to identify statistical 
differences between groups. p < 0.05 was considered statis-
tically significant. The results were analysed in Microsoft 
Excel. GraphPad Prism was used to create graphs, perform 
statistical analysis and calculate EC50 values.
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Table 1  All Western blotting and immunocytochemistry antibodies
Primary antibody target Source
TG2 (Cub7402) Abcam, UK
FN (F3648) Sigma-Aldrich, UK
αSMA (A2547) Sigma-Aldrich, UK
p-ERK1/2 (sc-7383 HRP) Santa Cruz Biotechnology, USA
ERK1/2 (sc-514302 HRP) Santa Cruz Biotechnology, USA
p-SMAD3 (ab52903) Abcam, UK
SMAD3 (ab40854) Abcam, UK
Syndecan-4 (ab24511) Santa Cruz Biotechnology, USA
GAPDH (ab8245) Abcam, UK
TGFβ1 (sc-130348 HRP) Santa Cruz Biotechnology, USA
Collagen type 1 (C2456) Sigma-Aldrich, UK
Secondary antibody Source
Swine anti-rabbit HRP-conjugated Dako, Denmark
Goat anti-mouse HRP-conjugated Dako, Denmark
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Human participants and/or animals This work did not involve any 
human participants or animals.
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